Similar articles

• Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy.

  Ruggenenti P, Cattaneo D, Loriga G, Ledda F, Motterlini N, Gherardi G, Orisio S, Remuzzi G. Ruggenenti P, et al. Hypertension. 2009 Sep;54(3):567-74. doi: 10.1161/HYPERTENSIONAHA.109.132522. Epub 2009 Jul 20. Hypertension. 2009. PMID: 19620516 Clinical Trial.
• Oral acetyl-L-carnitine therapy and insulin resistance.

  Ruggenenti P, van der Meer IM, Remuzzi G. Ruggenenti P, et al. Hypertension. 2010 Jun;55(6):e26. doi: 10.1161/HYPERTENSIONAHA.110.153767. Epub 2010 May 3. Hypertension. 2010. PMID: 20439816 No abstract available.
• [Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy].

  Demelia L, Solinas A, Gogoni G, Marongiu F, Besson A. Demelia L, et al. Recenti Prog Med. 1982 May;72(5):664-74. Recenti Prog Med. 1982. PMID: 6753066 Review. Italian. No abstract available.
• The effect of L-carnitine on insulin resistance in hemodialysed patients with chronic renal failure.

  Günal AI, Celiker H, Dönder E, Günal SY. Günal AI, et al. J Nephrol. 1999 Jan-Feb;12(1):38-40. J Nephrol. 1999. PMID: 10203002 Clinical Trial.
• [L-carnitine in peritoneal dialysis].

  De Vecchi AF, Arduini A, Di Liberato L, Bonomini M. De Vecchi AF, et al. G Ital Nefrol. 2011 Jul-Aug;28(4):393-400. G Ital Nefrol. 2011. PMID: 21809308 Review. Italian.